Imaging multidrug resistance with 4-[18F]fluoropaclitaxel

Kurdziel, Karen; Kalen, Joseph D.; Hirsch, Jerry I.; Wilson, John D.; Agarwal, Rakesh; Barrett, D.; Bear, Harry D.; McCumiskey, James

doi:10.1016/j.nucmedbio.2007.04.011

Cited by 42 publications

(41 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this hypothesis remains to be proven. Furthermore, increased uptake of both tracers was observed in the parotid and submandibular glands (45,48), suggesting that chemotherapy may contribute to radiotherapyrelated xerostomia in patients with locally advanced SCC of the head and neck.…”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

“…In (44,45), which is an endocrine organ that is located in the skull base. This hypophyseal accumulation can be explained by the fact that the posterior pituitary gland is not protected by the blood-brain barrier.…”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

“…k1, are the rate constants describing transport from plasma to tumor; k2 is the rate constant for clearance from tumor to plasma, and k3 and k4 are kinetic rate constants describing exchange between the two tumor compartments. k4 ¼ 0 for the irreversible two-tissue compartment model, which has been applied for kinetic modeling of [ (45,47), as well as in the parotid and submandibular glands (47,48). Increased tracer uptake has been measured in the vertebral body (45,47), which may clarify the drug-related neutropenia (49) and even the efficacy of docetaxel in patients with hormone refractory metastatic prostate cancer, as 90% of these patients have bone metastases, in particular, in the lumbar level of the spine (50).…”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

See 2 more Smart Citations

In Vivo Imaging as a Pharmacodynamic Marker

Veldt

Lammertsma

2014

Clinical Cancer Research

View full text Add to dashboard Cite

Although numerous anticancer drugs are widely used in the clinic, many questions remain about pharmacokinetics, biodistribution, toxicities, and efficacy. Positron emission tomography (PET) using radiolabeled drugs is a promising method to further understand the clinical behavior of anticancer agents. In addition, it may contribute to better guided treatment planning in individual patients with cancer. Among the available anticancer drugs, considerable experience has been gained with radiolabeling taxanes. At present, two radiolabeled taxanes, paclitaxel and docetaxel, are available as PET tracers.

show abstract

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Imaging as a Pharmacodynamic Marker

Veldt

Lammertsma

2014

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Some of the difference may be because both delivery (i.e., tumor blood flow) and retention contribute to sestamibi uptake and washout and may confound interpretation of sestamibi images for predicting drug transport (40). Ongoing work with PET probes of P-glycoprotein function in breast cancer may help in this regard (49,50). Other functional imaging modalities have been used to evaluate breast cancer response in the neoadjuvant setting, including PET with other radiopharmaceuticals, Doppler ultrasound (51), breast MRI, breast magnetic resonance spectroscopy (MRS) (52,53), and optical imaging (54).…”

Section: Response To Therapy Overviewmentioning

confidence: 99%

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2—Response to Therapy, Other Indications, and Future Directions

Lee

Rosen²,

Mankoff³

2009

J Nucl Med

View full text Add to dashboard Cite

and 2 Seattle Radiologists, Seattle, Washington Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provided an overview of clinical and biologic considerations in breast cancer and covered radionuclide imaging for detection and staging. Part 2 covers radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.Key Words: breast cancer; response to therapy; continuing education; molecular imaging; radionuclide imaging J Nucl Med 2009; 50:738-748 DOI: 10.2967/jnumed.108.061416 Breastcanceri s the most common non-skin type of cancer and the second leading cause of cancer mortality in women (1). Although its incidence continues to rise, mortality has declined over the past several years (1,2). The decline has been attributed to both early diagnosis and more effective treatment (2). Advances in molecular cancer biology have led to an increased understanding of the biologic factors that contribute to breast cancer pathogenesis and progression. This understanding has already led to new and effective treatments (3), and new targeted therapies continue to be developed and tested (4). Advances in breast cancer molecular biology have also yielded improvements in diagnosis through molecular pathology and molecular imaging (5,6).Part 1 of this review provided an overview of breast cancer clinical features and biology and reviewed radionuclide imaging for breast cancer detection and staging. Part 2 reviews applications to therapeutic monitoring and other indications such as toxicity monitoring, followed by highlights of future directions, including that of molecular imaging. RESPONSE TO THERAPY OverviewA wide range of systemic therapy options for breast cancer exists, and breast cancer is one of the more responsive solid tumors (7). Therefore, the evaluation of response to therapy is an important diagnostic need for breast cancer. Systemic therapy is given in 1 of the 3 following clinical settings: adjuvant (after completion of definitive locoregional surgery to treat residual or metastatic microscopic disease), neoadjuvant (primary systemic therapy given before definitive local surgery), or metastatic (systemic therapy of stage IV disease).For adjuvant therapy, there should be no residual macroscopic disease after surgery and, therefore, imaging is not helpful for response monitoring, exce...

show abstract

“…However, due to the higher spatial and faster kinetic resolution of quantitative positron emission tomography (PET), few tracers were labeled with positron emitters to visualize MDR. Most of these approaches used carbon-11 labeled drugs known to be Pgp substrates (e.g., paclitaxel) [7,8]. Several studies were performed using 11 C-verapamil (for an overview see [8]).…”

Section: Introductionmentioning

confidence: 99%